查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1728339

胜肽藥物偶聯物市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、類型、地區和競爭細分，2020-2030 年）

Peptide Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球胜肽藥物偶聯物市場價值為 6.2529 億美元，預計到 2030 年將達到 13.4715 億美元，預測期內複合年成長率為 13.65%。由於對標靶治療的需求不斷成長以及藥物輸送技術的創新，該市場正在經歷大幅成長。胜肽藥物偶聯物 (PDC) 代表一類新型治療方法，它結合了胜肽的選擇性靶向能力和抗癌劑的細胞毒性效力。透過提高對患病細胞的特異性，同時保護健康組織，PDC 比傳統化療具有更優異的安全性和有效性。全球癌症負擔的不斷增加以及精準醫療的轉變正在推動這一領域的研究和發展。作為抗體藥物偶聯物 (ADC) 的後續產品，PDC 的發展勢頭強勁，它提供更小、適應性更強的分子，具有增強的組織滲透性和降低的免疫原性。它們的應用正在迅速擴大，特別是在腫瘤學領域，治療效果、降低毒性和提高患者依從性至關重要。

市場概覽
預測期 2026-2030
2024年市場規模 6.2529億美元
2030年市場規模 13.4715億美元
2025-2030 年複合年成長率 13.65%
成長最快的領域 治療
最大的市場 北美洲

關鍵市場促進因素

癌症發生率上升

主要市場挑戰

開發成本高

主要市場趨勢

標靶治療日益受到關注

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球胜肽藥物偶聯物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品（镥、Melflufen、ANG1005、BT1718、CBX-12、其他管線產品）
    • 按類型（治療、診斷）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美胜肽藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲胜肽藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太胜肽藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美胜肽藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲胜肽藥物偶聯物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Novartis AG.
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16337

The Global Peptide Drug Conjugates Market was valued at USD 625.29 Million in 2024 and is projected to reach USD 1,347.15 Million by 2030, growing at a CAGR of 13.65% during the forecast period. This market is experiencing substantial growth due to rising demand for targeted therapies and innovation in drug delivery technologies. Peptide Drug Conjugates (PDCs) represent a novel class of therapeutics that combine the selective targeting ability of peptides with the cytotoxic potency of anti-cancer agents. By improving specificity toward diseased cells while sparing healthy tissue, PDCs offer a superior safety and efficacy profile over traditional chemotherapy. The increasing global burden of cancer, alongside the shift toward precision medicine, is fueling research and development in this space. PDCs have gained momentum as a follow-up to antibody-drug conjugates (ADCs), offering smaller, more adaptable molecules with enhanced tissue penetration and reduced immunogenicity. Their application is expanding rapidly, particularly in oncology, where treatment efficacy, reduced toxicity, and improved patient compliance are paramount.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 625.29 Million
Market Size 2030USD 1347.15 Million
CAGR 2025-203013.65%
Fastest Growing SegmentTherapeutic
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Cancer

The escalating global incidence of cancer is a major driver of the peptide drug conjugates market. As cancer remains one of the leading causes of morbidity and mortality, there is a pressing need for therapies that are both effective and less toxic. Traditional chemotherapy often lacks precision, affecting both cancerous and healthy cells, which results in severe side effects. In contrast, PDCs are engineered for targeted delivery, directing cytotoxic agents specifically to cancer cells and thereby minimizing damage to healthy tissues.

This targeted approach improves patient outcomes and quality of life. According to recent projections from the International Agency for Research on Cancer (IARC), approximately 35 million new cancer cases are expected globally by 2050-a 77% increase from 2022 figures. This upward trend is creating strong demand for safer and more effective treatment modalities, positioning PDCs as a compelling therapeutic solution.

Key Market Challenges

High Development Costs

One of the primary challenges in the peptide drug conjugates market is the high cost associated with their development. The process involves complex synthesis techniques, peptide-drug conjugation, and comprehensive preclinical and clinical evaluation. These stages are time-consuming and capital-intensive, posing significant barriers for small and mid-sized companies.

Large pharmaceutical companies currently dominate this space due to their greater financial resources and ability to manage the high risks and costs. However, innovation can be fostered through strategic collaborations, public-private partnerships, and advancements in development technologies that reduce manufacturing complexity and cost. Addressing the cost barrier will be crucial to facilitating wider adoption and broader participation in the market.

Key Market Trends

The Increasing Focus on Targeted Therapies

A major trend driving growth in the PDC market is the continued shift toward targeted therapies. PDCs exemplify this trend by offering precise drug delivery that minimizes systemic toxicity. The therapeutic peptides used in PDCs can be engineered to bind selectively to overexpressed receptors on cancer cells, ensuring localized action of the therapeutic payload.

This targeted mechanism mirrors the success of monoclonal antibodies in oncology and is further enhanced by the smaller size and better tissue penetration capabilities of peptides. PDCs are now being developed not only for oncology but also for diagnostic applications, utilizing radiolabeled or imaging agents for precise disease localization. This trend underscores the expanding versatility and potential of PDCs in personalized medicine.

Key Market Players

  • Novartis AG
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

Report Scope:

In this report, the Global Peptide Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Drug Conjugates Market, By Product:

  • Lutetium
  • Melflufen
  • ANG1005
  • BT1718
  • CBX-12
  • Other Pipeline Products

Peptide Drug Conjugates Market, By Type:

  • Therapeutic
  • Diagnostic

Peptide Drug Conjugates Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Drug Conjugates Market.

Available Customizations:

Global Peptide Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Drug Conjugates Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products)
    • 5.2.2. By Type (Therapeutic, Diagnostic)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Peptide Drug Conjugates Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Drug Conjugates Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
    • 6.3.2. Mexico Peptide Drug Conjugates Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
    • 6.3.3. Canada Peptide Drug Conjugates Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type

7. Europe Peptide Drug Conjugates Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Peptide Drug Conjugates Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
    • 7.3.2. Germany Peptide Drug Conjugates Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Peptide Drug Conjugates Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Peptide Drug Conjugates Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Peptide Drug Conjugates Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type

8. Asia-Pacific Peptide Drug Conjugates Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Peptide Drug Conjugates Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
    • 8.3.2. India Peptide Drug Conjugates Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
    • 8.3.3. South Korea Peptide Drug Conjugates Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
    • 8.3.4. Japan Peptide Drug Conjugates Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Peptide Drug Conjugates Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type

9. South America Peptide Drug Conjugates Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Drug Conjugates Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
    • 9.3.2. Argentina Peptide Drug Conjugates Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
    • 9.3.3. Colombia Peptide Drug Conjugates Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type

10. Middle East and Africa Peptide Drug Conjugates Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Drug Conjugates Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
    • 10.3.2. Saudi Arabia Peptide Drug Conjugates Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
    • 10.3.3. UAE Peptide Drug Conjugates Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bicycle Therapeutics PLC
  • 15.3. AstraZeneca PLC
  • 15.4. Cybrexa Therapeutics Inc
  • 15.5. Oncopeptides Inc.
  • 15.6. Angiochem Inc.
  • 15.7. Innovasium Soricimed Biopharma
  • 15.8. Theratechnologies Inc.
  • 15.9. Coherent Biopharma Co. Ltd
  • 15.10. Wuxi STA

16. Strategic Recommendation

17. About Us & Disclaimer